Forward Pharma Past Earnings Performance
Past criteria checks 0/6
Forward Pharma's earnings have been declining at an average annual rate of -91.3%, while the Biotechs industry saw earnings growing at 16.9% annually.
Key information
-91.3%
Earnings growth rate
-86.1%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -0.9% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Forward Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 0 | -1 | 4 | 0 |
| 31 Mar 22 | 0 | -1 | 4 | 0 |
| 31 Dec 21 | 0 | -2 | 4 | 0 |
| 30 Sep 21 | 0 | -4 | 3 | 0 |
| 30 Jun 21 | 0 | -5 | 3 | 0 |
| 31 Mar 21 | 0 | -6 | 3 | 0 |
| 31 Dec 20 | 0 | -6 | 3 | 0 |
| 30 Sep 20 | 0 | -5 | 3 | 0 |
| 30 Jun 20 | 0 | -4 | 3 | 1 |
| 31 Mar 20 | 0 | -4 | 4 | 1 |
| 31 Dec 19 | 0 | -4 | 4 | 1 |
| 30 Sep 19 | 0 | -5 | 5 | 1 |
| 30 Jun 19 | 0 | -6 | 6 | 2 |
| 31 Mar 19 | 0 | -8 | 7 | 2 |
| 31 Dec 18 | 0 | -9 | 9 | 3 |
| 30 Sep 18 | 0 | -19 | 12 | 5 |
| 30 Jun 18 | 0 | -29 | 13 | 15 |
| 31 Mar 18 | 0 | 444 | 15 | 18 |
| 31 Dec 17 | 0 | 917 | 19 | 13 |
| 30 Sep 17 | 0 | 939 | 19 | 20 |
| 30 Jun 17 | 0 | 940 | 18 | 25 |
| 31 Mar 17 | 0 | 454 | 16 | 35 |
| 31 Dec 16 | 0 | -33 | 14 | 41 |
| 30 Sep 16 | 0 | -53 | 13 | 39 |
Quality Earnings: 1FPB is currently unprofitable.
Growing Profit Margin: 1FPB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1FPB is unprofitable, and losses have increased over the past 5 years at a rate of 91.3% per year.
Accelerating Growth: Unable to compare 1FPB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1FPB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: 1FPB has a negative Return on Equity (-0.91%), as it is currently unprofitable.